Clinical trials: Breast Cancer Stage II
Breast Cancer
Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer.
This was a randomized, double-blind, placebo-controlled study conducted in Chinese women with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer, plus an open-label…
- Trial name
- NCT03671330
- Testing
- Ribociclib, NSAI: Letrozole or Anastrazole, Goserelin
- Where
- 24 sites in China
- Volunteers
- 327 people
- Sponsor
- Novartis Pharmaceuticals
Ductal Breast Carcinoma In Situ, Estrogen Receptor Positive
Accelerated Partial Breast Radiation Therapy Using High-Dose Rate Brachytherapy in Treating Patients With Early Stage Breast Cancer After Surgery
This phase II trial studies how well accelerated partial breast irradiation (APBI) using high-dose rate (HDR) brachytherapy works in treating patients with breast cancer that has not spread beyond the breast or the axillary lymph…
- Conditions
- Ductal Breast Carcinoma In Situ, Estrogen Receptor Positive, Invasive Breast Carcinoma, Progesterone Receptor Positive
- Trial name
- TRIUMPH-T (NCT02526498)
- Testing
- Accelerated Partial Breast Irradiation, High-Dose Rate Brachytherapy, Questionnaire Administration
- Where
- 10 sites in United States
- Volunteers
- 200 people
- Sponsor
- Rutgers, The State University of New Jersey
HER2/Neu Positive, HLA-A2 Positive Cells Present
Vaccine Therapy in Treating Patients With Stage IV HLA-A2 and HER2 Positive Breast or Ovarian Cancer Receiving Trastuzumab
This phase I/II trial studies the side effects of vaccine therapy and to see how well it works in treating patients with stage IV major histocompatibility complex, class I, A2 antigen (HLA-A2) and human epidermal growth factor…
- Conditions
- HER2/Neu Positive, HLA-A2 Positive Cells Present, Stage IV Breast Cancer, Stage IV Ovarian Cancer
- Trial name
- NCT00194714
- Testing
- HER-2/neu Peptide Vaccine, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Washington
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8
Improving Patient-Centered Communication in Breast Cancer Through Patient and Provider Interventions
This trial studies the effectiveness of two interventions on patient reported outcomes of patient centered communication and decision making about breast cancer treatment.
- Conditions
- Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8
- Trial name
- SHARES (NCT04549571)
- Testing
- Decision Aid iCanDecide - ESE website, Decision Aid iCanDecide - S website, Therapeutic Conventional Surgery
- Where
- 27 sites in United States
- Volunteers
- 614 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Breast Neoplasms, Metastases, Neoplasm
Vaccine and Chemotherapy for Previously Untreated Metastatic Breast Cancer
This study will evaluate the effectiveness of chemotherapy and a combination of vaccines to treat metastatic breast cancer (breast cancer that has spread beyond the breast) in patients whose cancer cells have a protein called…
- Trial name
- NCT00048893
- Testing
- recombinant fowlpox-CEA(6D)/TRICOM vaccine, recombinant vaccinia-CEA(6D)/TRICOM vaccine, filgrastim
- Where
- 2 sites in United States
- Volunteers
- 37 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
Single Fraction Elderly Breast Irradiation (SiFEBI)
Irradiation and Accelerated Partial Breast (IPAS) to this day remains a therapeutic concept whose validity is being assessed on its non-inferiority in terms of local control compared to whole breast irradiation.
- Trial name
- SIFEBI (NCT01727011)
- Testing
- IPAS
- Where
- France
- Volunteers
- 37 people
- Sponsor
- Centre Antoine Lacassagne
Breast Cancer
A Study of Debio 1347 Plus Fulvestrant in Patients With Metastatic Breast Cancer
The purpose of a phase Ib study is to find out the best or maximum tolerated dose of a medication or combination of medications.
- Trial name
- NCT03344536
- Testing
- Fulvestrant, Debio 1347
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Cancer
A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer
This multicenter, non-randomized, open-label, phase 2 study is designed to evaluate the safety and efficacy of pertuzumab (Perjeta) in combination with trastuzumab (Herceptin) and anthracycline-based chemotherapy as neoadjuvant…
- Trial name
- BERENICE (NCT02132949)
- Testing
- 5-Fluorouracil, Cyclophosphamide, Docetaxel
- Where
- 80 sites in United States, Canada and 10 more
- Volunteers
- 401 people
- Sponsor
- Hoffmann-La Roche
Advanced Breast Cancer
A Study of Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase Inhibitor
This study aimed at evaluating the safety and efficacy of everolimus plus exemestane in Chinese postmenopausal women with ER+ HER2- locally advanced, recurrent, or metastatic breast cancer after recurrence or progression on…
- Trial name
- BOLERO-5 (NCT03312738)
- Testing
- Everolimus, Exemestane
- Where
- 15 sites in China
- Volunteers
- 159 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer
Preoperative Cisplatin and Bevacizumab in ER-, PR-, HER2 Negative Breast Cancer
The purpose of this study is to find out what effect taking cisplatin in combination with bevacizumab before surgery and then standard chemotherapy plus bevacizumab after surgery will have on participants with Estrogen Receptor…
- Trial name
- NCT00580333
- Testing
- cisplatin, bevacizumab, doxorubicin
- Where
- 3 sites in United States
- Volunteers
- 51 people
- Sponsor
- Massachusetts General Hospital
Metastatic Triple Negative Breast Cancer
L-NMMA Plus Taxane Chemotherapy in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients
This is a Phase Ib/II study assessing the maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), recommended Phase 2 dose (RP2D), and efficacy of L-NMMA when combined with docetaxel in refractory locally advanced or…
- Trial name
- NCT02834403
- Testing
- L-NMMA, Docetaxel, Amlodipine
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- The Methodist Hospital Research Institute
Stage IIA Breast Cancer, Stage IIB Breast Cancer
Chemotherapy Before Surgery and Tissue Sample Collection in Patients With Stage IIA-IIIC Breast Cancer
This pilot clinical trial studies chemotherapy before surgery and tissue sample collection in patients with stage IIA-IIIC breast cancer.
- Conditions
- Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer
- Trial name
- NCT01897441
- Testing
- Cyclophosphamide, Cytology Specimen Collection Procedure, Doxorubicin Hydrochloride
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Albert Einstein College of Medicine
Breast Cancer
Fulvestrant Plus Enzalutamide in ER+/Her2- Advanced Breast Cancer
A phase 2 study to evaluate the tolerability and clinical activity of adding enzalutamide to fulvestrant treatment in women with advanced breast cancer that are ER and/or PR positive and Her2 normal.
- Trial name
- NCT02953860
- Testing
- Fulvestrant with Enzalutamide
- Where
- 3 sites in United States
- Volunteers
- 32 people
- Sponsor
- University of Colorado, Denver
Breast Cancer, Recurrent Breast Cancer
Paclitaxel, Carboplatin, and Panitumumab in Treating Patients With Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
- Trial name
- NCT01009983
- Testing
- panitumumab, paclitaxel, carboplatin
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- Wake Forest University Health Sciences
Breast Cancer
Ixabepilone and Cyclophosphamide as Neoadjuvant Therapy in HER-2 Negative Breast Cancer
We propose to evaluate ixabepilone in combination with cyclophosphamide for the neoadjuvant treatment of locally advanced breast cancer.
- Trial name
- NCT00866905
- Testing
- Ixabepilone, Cyclophosphamide
- Where
- 20 sites in United States
- Volunteers
- 168 people
- Sponsor
- SCRI Development Innovations, LLC
Breast Cancer
Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery
RATIONALE: It is not yet know whether higher per daily radiation therapy is equally as effective as standard per daily radiation therapy in treating breast cancer.
- Trial name
- NCT01349322
- Testing
- Standard fractionation whole breast irradiation, Hypofractionated whole breast irradiation, Concurrent boost
- Where
- 415 sites in United States, Canada and 6 more
- Volunteers
- 2,354 people
- Sponsor
- Radiation Therapy Oncology Group
Breast Cancer
A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Neoadjuvant Treatment for Participants With Early Stage Triple Negative Breast Cancer
This is a randomized, double-blind, placebo-controlled, multicenter, pre-operative Phase II study designed to estimate the efficacy of ipatasertib combined with paclitaxel chemotherapy versus placebo combined with paclitaxel…
- Trial name
- NCT02301988
- Testing
- Ipatasertib, Paclitaxel
- Where
- 42 sites in United States, Portugal and 1 more
- Volunteers
- 151 people
- Sponsor
- Genentech, Inc.
Breast Cancer
Dovitinib Plus an Aromatase Inhibitor for Metastatic Breast Cancer
This study is for women with confirmed hormone receptor positive HER-2 negative advanced breast cancer with evidence of disease resistance to an aromatase inhibitor.
- Trial name
- NCT01484041
- Testing
- Dovitinib, Aromatase Inhibitors
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Georgetown University
Breast Cancer
Preoperative Fulvestrant With or Without Enzalutamide in ER+/Her2- Breast Cancer
This is a randomized two arm phase II study to further evaluate the efficacy of fulvestrant plus enza compared to single agent fulvestrant in postmenopausal women with locally advanced AR+/ER+/Her2- BC who will have local surgery…
- Trial name
- NCT02955394
- Testing
- Enzalutamide, Fulvestrant
- Where
- 3 sites in United States
- Volunteers
- 61 people
- Sponsor
- University of Colorado, Denver
Breast Cancer
Internal Radiation Therapy After Lumpectomy in Treating Women With Ductal Carcinoma in Situ
RATIONALE: Internal radiation uses radioactive material placed directly into or near a tumor to kill tumor cells. Giving internal radiation therapy using a special radiation therapy device may kill any tumor cells that remain…
- Trial name
- NCT00290654
- Testing
- Tamoxifen, Lumpectomy, brachytherapy
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Masonic Cancer Center, University of Minnesota